within Pharmacolibrary.Drugs.ATC.J;

model J01AA15
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.34,
    Cl             = 0.16999999999999998,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.19,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005633333333333334,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Omadacycline is a modern aminomethylcycline antibiotic, structurally related to tetracyclines, used for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It is approved for clinical use and is active against a broad spectrum of Gram-positive and some Gram-negative bacteria.</p><h4>Pharmacokinetics</h4><p>Healthy adult subjects, both sexes, 18–65 years, following single and multiple oral or intravenous doses.</p><h4>References</h4><ol><li><p>Rodvold, KA, &amp; Pai, MP (2019). Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 69(Suppl 1) S16–S22. DOI:<a href=&quot;https://doi.org/10.1093/cid/ciz309&quot;>10.1093/cid/ciz309</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31367744/&quot;>https://pubmed.ncbi.nlm.nih.gov/31367744</a></p></li><li><p>Leviton, IM, &amp; Amodio-Groton, M (2022). Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection. <i>Clinical drug investigation</i> 42(3) 193–197. DOI:<a href=&quot;https://doi.org/10.1007/s40261-022-01119-9&quot;>10.1007/s40261-022-01119-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35192150/&quot;>https://pubmed.ncbi.nlm.nih.gov/35192150</a></p></li><li><p>Rodvold, KA, et al., &amp; Pai, MP (2020). Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics. <i>Clinical pharmacokinetics</i> 59(4) 409–425. DOI:<a href=&quot;https://doi.org/10.1007/s40262-019-00843-4&quot;>10.1007/s40262-019-00843-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31773505/&quot;>https://pubmed.ncbi.nlm.nih.gov/31773505</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01AA15;
